Spasticity – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：85頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Spasticity – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Spasticity - Pipeline Review, H2 2012', provides an overview of the Spasticity therapeutic pipeline. This report provides information on the therapeutic development for Spasticity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spasticity. 'Spasticity - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Spasticity.
- A review of the Spasticity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Spasticity pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Spasticity.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Spasticity pipeline depth and focus of Spasticity therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Spasticity - Pipeline Review, H2 2012', provides an overview of the Spasticity therapeutic pipeline. This report provides information on the therapeutic development for Spasticity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spasticity. 'Spasticity - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Spasticity.
- A review of the Spasticity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Spasticity pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Spasticity.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Spasticity pipeline depth and focus of Spasticity therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Spasticity Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Spasticity 10
Spasticity Therapeutics under Development by Companies 12
Spasticity Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Pre-Clinical Stage Products 18
Comparative Analysis 18
Spasticity Therapeutics – Products under Development by Companies 19
Spasticity Therapeutics – Products under Investigation by Universities/Institutes 20
Companies Involved in Spasticity Therapeutics Development 21
Allergan, Inc. 21
XenoPort, Inc. 22
Ipsen S.A. 23
Novartis AG 24
Merz GmbH & Co. KGaA 25
Sun Pharmaceutical Industries Limited 26
IMPAX Laboratories, Inc. 27
GW Pharmaceuticals plc 28
Sanochemia Pharmazeutika AG 29
Raptor Pharmaceuticals Corp. 30
Osmotica Pharmaceutical Corp. 31
Concert Pharmaceuticals, Inc. 32
Spasticity – Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
Sativex - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
OS-440 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Tezampanel - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Dysport - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Tolperisone - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Tolperisone - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Arbaclofen Placarbil - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Botox - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Botulinum Toxin Type A - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Xeomin - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
BGG-492 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Baclofen - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
IPX056 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
MEOPA - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Nabilone - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Baclofen GRS - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
SUN 09 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
CTP-354 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Neurox - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Spasticity Therapeutics – Drug Profile Updates 67
Spasticity Therapeutics – Discontinued Products 76
Spasticity Therapeutics - Dormant Products 77
Spasticity – Product Development Milestones 78
Featured News & Press Releases 78
Jun 22, 2012: German G-BA Establishes Positive Additional Benefit Of Sativex In Multiple Sclerosis Spasticity 78
Feb 07, 2012: Almirall Starts New Wave Of Regulatory Submissions For Sativex In Europe 78
Dec 22, 2011: GW Pharmaceuticals Receives Swedish Approval For Sativex 79
Nov 22, 2011: GW Files New Regulatory Application To Expand Sativex Approvals To Additional European Countries 80
Nov 17, 2011: GW Pharmaceuticals Obtains European Patent For Sativex Formulation 80
Nov 17, 2011: Merz To Present XEOMIN Data At 72nd Annual Assembly Of American Academy Of Physical Medicine And Rehabilitation 80
Nov 14, 2011: Concert Pharmaceuticals Presents Preclinical Data Of C-21191 At Neuroscience 2011 81
Oct 19, 2011: Concert Pharmaceuticals To Present Data On Deuterium-Containing GABAA Modulators At Neuroscience 2011 82
Jul 18, 2011: GW Pharmaceuticals Launches Sativex In Denmark 83
Jul 04, 2011: GW Pharmaceuticals Launches Sativex In Germany 83
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 84
Contact Us 85
Disclaimer 85
List of Tables
Number of Products Under Development for Spasticity, H2 2012 10
Products under Development for Spasticity – Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 20
Allergan, Inc., H2 2012 21
XenoPort, Inc., H2 2012 22
Ipsen S.A., H2 2012 23
Novartis AG, H2 2012 24
Merz GmbH & Co. KGaA, H2 2012 25
Sun Pharmaceutical Industries Limited, H2 2012 26
IMPAX Laboratories, Inc., H2 2012 27
GW Pharmaceuticals plc, H2 2012 28
Sanochemia Pharmazeutika AG, H2 2012 29
Raptor Pharmaceuticals Corp., H2 2012 30
Osmotica Pharmaceutical Corp., H2 2012 31
Concert Pharmaceuticals, Inc., H2 2012 32
Assessment by Monotherapy Products, H2 2012 33
Assessment by Stage and Route of Administration, H2 2012 35
Assessment by Stage and Molecule Type, H2 2012 37
Spasticity Therapeutics – Drug Profile Updates 67
Spasticity Therapeutics – Discontinued Products 76
Spasticity Therapeutics – Dormant Products 77
List of Figures
Number of Products under Development for Spasticity, H2 2012 10
Products under Development for Spasticity – Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 33
Assessment by Route of Administration, H2 2012 34
Assessment by Stage and Route of Administration, H2 2012 35
Assessment by Molecule Type, H2 2012 36
Assessment by Stage and Molecule Type, H2 2012 37
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Spasticity Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Spasticity 10
Spasticity Therapeutics under Development by Companies 12
Spasticity Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Pre-Clinical Stage Products 18
Comparative Analysis 18
Spasticity Therapeutics – Products under Development by Companies 19
Spasticity Therapeutics – Products under Investigation by Universities/Institutes 20
Companies Involved in Spasticity Therapeutics Development 21
Allergan, Inc. 21
XenoPort, Inc. 22
Ipsen S.A. 23
Novartis AG 24
Merz GmbH & Co. KGaA 25
Sun Pharmaceutical Industries Limited 26
IMPAX Laboratories, Inc. 27
GW Pharmaceuticals plc 28
Sanochemia Pharmazeutika AG 29
Raptor Pharmaceuticals Corp. 30
Osmotica Pharmaceutical Corp. 31
Concert Pharmaceuticals, Inc. 32
Spasticity – Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
Sativex - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
OS-440 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Tezampanel - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Dysport - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Tolperisone - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Tolperisone - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Arbaclofen Placarbil - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Botox - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Botulinum Toxin Type A - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Xeomin - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
BGG-492 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Baclofen - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
IPX056 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
MEOPA - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Nabilone - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Baclofen GRS - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
SUN 09 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
CTP-354 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Neurox - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Spasticity Therapeutics – Drug Profile Updates 67
Spasticity Therapeutics – Discontinued Products 76
Spasticity Therapeutics - Dormant Products 77
Spasticity – Product Development Milestones 78
Featured News & Press Releases 78
Jun 22, 2012: German G-BA Establishes Positive Additional Benefit Of Sativex In Multiple Sclerosis Spasticity 78
Feb 07, 2012: Almirall Starts New Wave Of Regulatory Submissions For Sativex In Europe 78
Dec 22, 2011: GW Pharmaceuticals Receives Swedish Approval For Sativex 79
Nov 22, 2011: GW Files New Regulatory Application To Expand Sativex Approvals To Additional European Countries 80
Nov 17, 2011: GW Pharmaceuticals Obtains European Patent For Sativex Formulation 80
Nov 17, 2011: Merz To Present XEOMIN Data At 72nd Annual Assembly Of American Academy Of Physical Medicine And Rehabilitation 80
Nov 14, 2011: Concert Pharmaceuticals Presents Preclinical Data Of C-21191 At Neuroscience 2011 81
Oct 19, 2011: Concert Pharmaceuticals To Present Data On Deuterium-Containing GABAA Modulators At Neuroscience 2011 82
Jul 18, 2011: GW Pharmaceuticals Launches Sativex In Denmark 83
Jul 04, 2011: GW Pharmaceuticals Launches Sativex In Germany 83
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 84
Contact Us 85
Disclaimer 85
List of Tables
Number of Products Under Development for Spasticity, H2 2012 10
Products under Development for Spasticity – Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 20
Allergan, Inc., H2 2012 21
XenoPort, Inc., H2 2012 22
Ipsen S.A., H2 2012 23
Novartis AG, H2 2012 24
Merz GmbH & Co. KGaA, H2 2012 25
Sun Pharmaceutical Industries Limited, H2 2012 26
IMPAX Laboratories, Inc., H2 2012 27
GW Pharmaceuticals plc, H2 2012 28
Sanochemia Pharmazeutika AG, H2 2012 29
Raptor Pharmaceuticals Corp., H2 2012 30
Osmotica Pharmaceutical Corp., H2 2012 31
Concert Pharmaceuticals, Inc., H2 2012 32
Assessment by Monotherapy Products, H2 2012 33
Assessment by Stage and Route of Administration, H2 2012 35
Assessment by Stage and Molecule Type, H2 2012 37
Spasticity Therapeutics – Drug Profile Updates 67
Spasticity Therapeutics – Discontinued Products 76
Spasticity Therapeutics – Dormant Products 77
List of Figures
Number of Products under Development for Spasticity, H2 2012 10
Products under Development for Spasticity – Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 33
Assessment by Route of Administration, H2 2012 34
Assessment by Stage and Route of Administration, H2 2012 35
Assessment by Molecule Type, H2 2012 36
Assessment by Stage and Molecule Type, H2 2012 37
